Imatinib for CML: How a Genetic Mutation Changed Cancer Treatment

For decades, cancer treatment often focused on attacking rapidly dividing cells. The development of imatinib for chronic myeloid leukemia (CML) helped demonstrate a different approach: identifying the molecular abnormality driving cancer and targeting it directly.

Imatinib is a tyrosine kinase inhibitor (TKI) that targets the abnormal BCR::ABL1 protein associated with CML. By blocking this cancer-driving kinase, imatinib can interfere with signals that promote leukemia-cell growth and survival.

What Is the Philadelphia Chromosome?

One of the defining genetic abnormalities associated with CML is the Philadelphia chromosome.

It results from a rearrangement between chromosomes 9 and 22, creating the BCR::ABL1 fusion gene. This gene produces an abnormal tyrosine kinase protein that remains continuously active.

Instead of normal cellular signaling being carefully regulated, BCR::ABL1 can continuously send signals that encourage leukemia cells to grow and survive.

This molecular abnormality became an important target for precision cancer treatment.

How Does Imatinib Work?

Imatinib works by inhibiting the activity of BCR::ABL1 tyrosine kinase.

The medicine binds to the kinase and interferes with its signaling activity. This reduces the abnormal signals that contribute to uncontrolled growth of CML cells.

In simple terms:

BCR::ABL1 drives the signal → imatinib blocks the kinase → abnormal growth signaling is reduced.

This mechanism is a key reason imatinib became a landmark example of targeted cancer therapy.

Imatinib and Chronic Myeloid Leukemia

For patients with CML whose disease is driven by BCR::ABL1, tyrosine kinase inhibitors such as imatinib have fundamentally changed treatment.

Instead of relying solely on broadly acting cancer therapies, physicians can target a specific molecular abnormality associated with the disease.

Treatment response is monitored using clinical and molecular assessments, which can help healthcare professionals evaluate how effectively the disease is being controlled.

The specific treatment strategy depends on factors such as disease phase, treatment respo